Dr. Sarah Mitchell, MD
Board Certified Endocrinologist
Clinical Content Lead · GLP-1.health
Specialty
Endocrinology & Metabolic Medicine
Editorial Role
Clinical Content Lead
GLP-1 Health Editorial Board
About
Dr. Mitchell has spent 15 years watching obesity medicine transform from a specialty with few real tools into one of the most drug-assisted fields in medicine. She was among the early adopters of GLP-1 therapy at Stanford and has since guided hundreds of patients through these medications — the results and the hard parts alike.
Education & Training
Doctor of Medicine (MD)
Stanford University School of Medicine
Completed 2006
Residency, Internal Medicine
UCSF Medical Center
Completed 2009
Fellowship, Endocrinology & Metabolism
Johns Hopkins Hospital
Completed 2011
Selected Publications
"Long-term outcomes of GLP-1 receptor agonist therapy in non-diabetic obesity"
"Cardiovascular benefits of semaglutide beyond glycemic control"
"Patient adherence patterns with injectable vs oral GLP-1 agents"
Board Certifications
- American Board of Internal Medicine (ABIM) – Endocrinology, Diabetes & Metabolism
- American Board of Obesity Medicine (ABOM)
- Fellow, American College of Endocrinology (FACE)
Articles Reviewed
What is GLP-1? A Complete Guide to Weight Loss Injections
Who Should NOT Take GLP-1 Medications? Full Contraindications List
What Happens When You Stop Taking GLP-1 Medications?
The Future of GLP-1: New Drugs Coming in 2026
Semaglutide Weight Loss Results After 6 Months: What the Data Actually Shows
Who Qualifies for GLP-1 Injections? BMI Thresholds, Medical Criteria, and the Gray Areas
Wegovy vs. Ozempic in 2026: Same Molecule, Very Different Drugs
Semaglutide Constipation: Natural Remedies That Actually Help
The Complete GLP-1 Diet: Foods That Work With These Medications (and Foods That Work Against Them)
GLP-1 Medications and Long-Term Heart Safety: What the Evidence Actually Shows
Ozempic and PCOS: The Weight Loss Connection, Real Patient Outcomes, and What the Research Shows
Tirzepatide vs. Semaglutide at 72 Weeks: A Head-to-Head Analysis of the Data
Finding Zepbound (Tirzepatide) Clinics Near You in 2026: A Practical Guide
High-Protein Shake Recipes for GLP-1 Users: Practical, Easy, and Designed for Small Appetites
Liraglutide (Victoza/Saxenda): The Original GLP-1 That Still Has a Role in 2026
GLP-1 Medications: Complete 2026 Comparison Guide (Wegovy, Ozempic, Zepbound, Mounjaro)
GLP-1 Medication Availability in 2026: Shortage Status, Supply Updates & What to Do
Editorial Standards
Content reviewed by this physician is produced in accordance with FDA guidelines, Mayo Clinic clinical protocols, and peer-reviewed medical literature. Last updated March 2026.